Improved oral bioavailability of valsartan using proliposomes: Design, characterization and in vivo pharmacokinetics

Drug Development and Industrial Pharmacy

Volumn 41, Issue 12, 2015, Pages 2077-2088

  Nekkanti, Vijaykumar ^a   Venkatesan, Natarajan ^b   Wang, Zhijun ^a   Betageri, Guru V ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

Author keywords

Caco 2; Dissolution; Oral bioavailability; PAMPA; Pharmacokinetics; Proliposomes; Valsartan

Indexed keywords

BILE SALT; CHOLESTEROL; LIPOSOME; PHOSPHOLIPID; PROLIPOSOME; PURIFIED WATER; TETRAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VALSARTAN; PRODRUG;

ACID DISSOCIATION CONSTANT; ANGLE OF REPOSE; ANIMAL EXPERIMENT; APPARENT PERMEABILITY; AREA UNDER THE CURVE; ARTICLE; CACO 2 CELL LINE; CALORIMETRY; CONTROLLED STUDY; CRYOELECTRON MICROSCOPY; DIALYSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG RETENTION; DRUG SOLUBILITY; DRUG STABILITY; ENCAPSULATION; HUMAN; HUMAN CELL; HYDRATION; INTESTINE PERFUSION; LIPOPHILICITY; LIPOSOME MEMBRANE; MALE; MAXIMUM PLASMA CONCENTRATION; MEMBRANE VESICLE; NONHUMAN; PARALLEL ARTIFICIAL MEMBRANE PERMEATION ASSAY; PARTICLE SIZE; PHARMACOLOGICAL PARAMETERS; PHASE TRANSITION; PHYSICAL CHEMISTRY; POLYDISPERSITY INDEX; RAT; STOMACH JUICE; STOMACH PH; SUSPENSION; THIN FILM HYDRATION; TRANSMISSION ELECTRON MICROSCOPY; VESICLE SIZE; VOLUME OF DISTRIBUTION; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; DRUG DESIGN; HUMANS; LIPOSOMES; MALE; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; VALSARTAN;

EID: 84949571013     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2015.1075026     Document Type: Article

References (61)

1. Janga KY, Jukanti R, Velpula A, et al. Bioavailability enhancement of zaleplon via proliposomes: role of surface charge. Eur J Pharm Biopharm 2012;80:347-57.
2. Xiao Y, Song Y, Chen Z, Ping Q. Preparation of silymarin proliposomes and its pharmacokinetics in rats. Yao xue xue bao=Acta Pharmacol Sin 2005;40:758-63.
3. Xu H, He L, Nie S, et al. Optimized preparation of vinpocetine proliposomes by a novel method and in vivo evaluation of its pharmacokinetics in New Zealand rabbits. J Control Release 2009;140:61-8.
4. Bobbala SKR, Veerareddy PR. Formulation, evaluation, and pharmacokinetics of isradipine proliposomes for oral delivery. J Liposome Res 2012;22:285-94.
5. Hiremath PS, Soppimath KS, Betageri GV. Proliposomes of exemestane for improved oral delivery: formulation andin vitro evaluation using PAMPA, Caco-2 and rat intestine. Int J Pharm 2009;380:96-104.
6. Katare O, Vyas S, Dixit V. Effervescent granule based proliposomes of ibuprofen. J Microencapsul J Microencapsul 1990;7:455-62.
7. Katare O, Vyas S, Dixit V. Proliposomes of indomethacin for oral administration. J Microencapsul 1991;8:1-7.
8. Potluri P, Betageri GV. Mixed-micellar proliposomal systems for enhanced oral delivery of progesterone. Drug Deliv 2006;13:227-32.
9. Nekkanti V, Venkatesan N, Betageri GV. Proliposomes for oral delivery: progress and challenges. Curr Pharm Biotechnol 2014;16:303-12.
10. Velpula A, Jukanti R, Janga KY, et al. Proliposome powders for enhanced intestinal absorption and bioavailability of raloxifene hydrochloride: effect of surface charge. Drug Dev Ind Pharm 2013;39:1895-906.
11. Sheue Nee Ling S, Magosso E, Abdul Karim Khan N, et al. Enhanced oral bioavailability and intestinal lymphatic transport of a hydrophilic drug using liposomes. Drug Dev Ind Pharm 2006;32:335-45.
12. Smith DG, Cerulli A, Frech FH. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis. Clin Ther 2005;27:951-9.
13. Criscione L, Bradley WA, Bühlmayer P, et al. Valsartan: preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc Drug Rev 1995;13:230-50.
14. Flesch G, Müller P, Lloyd P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol 1997;52:115-20.
15. Brookman LJ, Rolan PE, Benjamin IS, et al. Pharmacokinetics of valsartan in patients with liver disease. Clin Pharmacol Ther 1997;62:272-8.
16. Wu C-Y, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharma Res 2005;22:11-23.
17. Cappello B, Di Maio C, Iervolino M, Miro A. Improvement of solubility and stability of valsartan by hydroxypropyl-\ boldbetacyclodextrin. J Incl Phenom Macrocycl Chem 2006;54(3-4):289-94.
18. Parmar B, Mandal S, Petkar K, et al. Valsartan loaded solid lipid nanoparticles: development, characterization, and in vitro and ex vivo evaluation. Int J Pharm Sci Nanotechnol 2011;4:1483-90.
19. Yan Y-D, Sung JH, Kim KK, et al. Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes. Int J Pharma 2012;422:202-10.
20. Tarur VR, Sathe DG, Rao N, et al. Process for the preparation of micronized valsartan. U. S. Patent Application 12/304, 148; 2009.
21. Dixit AR, Rajput SJ, Patel SG. Preparation and bioavailability assessment of SMEDDS containing valsartan. AAPS PharmSciTech 2010;11:314-21.
22. Gurrapu A, Jukanti R, Bobbala SR, et al. Improved oral delivery of valsartan from maltodextrin based proniosome powders. Adv Powder Technol 2012;23:583-90.
23. Cao Q-R, Liu Y, Xu W-J, et al. Enhanced oral bioavailability of novel mucoadhesive pellets containing valsartan prepared by a dry powder-coating technique. Int J Pharm 2012;434:325-33.
24. Porter CJ, Charman WN. Intestinal lymphatic drug transport: an update. Adv Drug Deliv Rev 2001;50:61-80.
25. Chu C, Tong S-S, Xu Y, et al. Proliposomes for oral delivery of dehydrosilymarin: preparation and evaluation in vitro and in vivo. Acta Pharmacol Sin 2011;32:973-80.
26. Staniforth J, Aulton M. Pharmaceutics: the science dosage form design. Edinburgh, Scotland: Churchill Livingstone; 1988:610-36.
27. Galia E, Nicolaides E, Hörter D, et al. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharma Res 1998;15:698-705.
28. Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 2001;46:27-43.
29. Augustijns PF, Bradshaw TP, Gan L-S L, et al. Evidence for a polarized efflux system in Caco-2 cells capable of modulating cyclosporine A transport. Biochem Biophys Res Commun 1993;197:360-5.
30. Bermejo M, Avdeef A, Ruiz A, et al. PAMPA-a drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur J Pharm Sci 2004;21:429-41.
31. Song K-H, Chung S-J, Shim C-K. Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts. J Control Release 2005;106:298-308.
32. Ravis WR, Feldman S. Effect of enzyme-inducing and enzymeinhibiting agents on drug absorption I: 3-O-methylglucose transport in rats. J Pharma Sci 1978;67:245-8.
33. Barthe L, Woodley J, Houin G. Gastrointestinal absorption of drugs: methods and studies. Fundam Clin Pharmacol 1999;13:154-68.
34. Issa C, Gupta P, Bansal AK. Implications of density correction in gravimetric method for water flux determination using rat singlepass intestinal perfusion technique: a technical note. AAPS PharmSciTech 2003;4:44-9.
35. Jukanti R, Mateti A, Bandari S, Veerareddy PR. Transdermal delivery of acyclovir sodium via carbopol gels: role of chemical permeation enhancers. Lett Drug Des Discov 2011;8:381-9.
36. Tosco P, Rolando B, Fruttero R, et al. Physicochemical profiling of sartans: a detailed study of ionization constants and distribution coefficients. Helv Chim Acta 2008;91:468-82.
37. Gregoriadis G, Davis C. Stability of liposomes invivo and invitro is promoted by their cholesterol content and the presence of blood cells. Biochem Biophys Res Commun 1979;89:1287-93.
38. Betageri G. Liposomal encapsulation and stability of dideoxyinosine triphosphate. Drug Dev Ind Pharm 1993;19:531-9.
39. Maurer N, Fenske DB, Cullis PR. Developments in liposomal drug delivery systems. Expert Opin Biol Ther 2001;1:923-47.
40. Elorza M, Garcia De La Cruz F, San Juan R, et al. Linkages between macromolecules in Candida albicans cell wall. Arch Med Res 1992;24:305-10.
41. Dan N. Effect of liposome charge and PEG polymer layer thickness on cell-liposome electrostatic interactions. Biochim Biophys Acta 2002;1564:343-8.
42. Dragicevic-Curic N, Gräfe S, Gitter B, et al. Surface charged temoporfin-loaded flexible vesicles: in vitro skin penetration studies and stability. Int J Pharm 2010;384:100-8.
43. Wu J, Lee A, Lu Y, Lee RJ. Vascular targeting of doxorubicin using cationic liposomes. Int J Pharm 2007;337:329-35.
44. Rengel RG, Barišić K, Pavelić Ž, et al. High efficiency entrapment of superoxide dismutase into mucoadhesive chitosan-coated liposomes. Eur J Pharm Sci 2002;15:441-8.
45. Staniforth J. Powder flow. In: Aulton ME, ed. Pharmaceutics: the science of dosage form design. 2nd ed. Edinburgh, Scotland: Churchill Livingstone; 2002:197-210.
46. Cócera M, López O, Coderch L, et al. Alterations in stratum corneum lipid liposomes due to the action of Triton X-100: influence of the level of ceramides on this process. J Control Release 2000;68:387-96.
47. Du B, Li Y, Li X, Youmei A, et al. Preparation, characterization and in vivo evaluation of 2-methoxyestradiol-loaded liposomes. Int J Pharm 2010;384:140-7.
48. Yanamandra S, Venkatesan N, Kadajji VG, et al. Proliposomes as a drug delivery system to decrease the hepatic first-pass metabolism: Case study using a model drug. Eur J Pharm Sci 2014;64:26-36.
49. KV S, Devi GS, Mathew ST. Liposomal formulations of serratiopeptidase: in vitro studies using PAMPA and Caco-2 models. Mol Pharm 2007;5:92-7.
50. Kansy M, Senner F, Gubernator K. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem 1998;41:1007-10.
51. Kerns EH, Di L, Petusky S, et al. Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery. J Pharm Sci 2004;93:1440-53.
52. Watanabe E, Takahashi M, Hayashi M. A possibility to predict the absorbability of poorly water-soluble drugs in humans based on rat intestinal permeability assessed by an in vitro chamber method. Eur J Pharm Biopharm 2004;58:659-65.
53. Palasciano G, Tytgat GN. Cell type-dependent effect of phospholipid and cholesterol on bile salt cytotoxicity. Gastroenterology 1991;101:457-64.
54. Planas M, Gonzalez P, Rodriguez L, et al. Noninvasive percutaneous induction of topical analgesia by a new type of drug carrier, and prolongation of local pain insensitivity by anesthetic liposomes. Anesth Analg 1992;75:615-21.
55. Cevc G, Schätzlein A, Gebauer D, Blume G. Ultra-high efficiency of drugs and peptide transfer through the intact skin by means of novel drug carriers, transfersomes. Cardiff, UK: STS Publishing; 1993.
56. Cevc G, Schätzlein A, Blume G. Transdermal drug carriers: basic properties, optimization and transfer efficiency in the case of epicutaneously applied peptides. J Control Release 1995;36:3-16.
57. Hochman J, Artursson P. Mechanisms of absorption enhancement and tight junction regulation. J Control Release 1994;29:253-67.
58. Werner U, Kissel T, Reers M. Effects of permeation enhancers on the transport of a peptidomimetic thrombin inhibitor (CRC 220) in a human intestinal cell line (Caco-2). Pharm Res 1996;13:1219-27.
59. Sharma V, McNeill JH. To scale or not to scale: the principles of dose extrapolation. Br J Clin Pharmacol 2009;157:907-21.
60. Waldmeier F, Flesch G, Mu Ller P, et al. Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica 1997;27:59-71.
61. Bissessor N, White H. Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction. Vasc Health Risk Manag 2007;3:425.